Pure red cell aplasia: The second hundred years

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Pure red cell aplasia (PRCA) is a rare syndrome.
• Characterized by anemia, reticulocytopenia, and absent erythroid precursors.
• PRCA can be primary (autoimmune/clonal) or secondary to various conditions.

Purpose of the Study:

• To review the classification, diagnosis, and therapy of PRCA.
• To highlight new developments in understanding PRCA.
• To discuss challenges and opportunities in PRCA management.

Main Methods:

• Literature review of PRCA.
• Focus on T-cell roles and mutations.
• Examination of clonal hematopoiesis.
• Review of novel therapies for refractory PRCA and post-transplant PRCA.

Main Results:

• PRCA insights have advanced understanding of erythropoiesis regulation.
• New developments involve T-cell regulatory mutations and clonal hematopoiesis.
• Therapeutic advancements are emerging for refractory PRCA.

Conclusions:

• PRCA management requires a comprehensive approach.
• Understanding T-cell and clonal hematopoiesis roles is crucial.
• New therapies offer hope for refractory PRCA and transplant-related cases.